former Chief Medical Officer · Tvardi Therapeutics, Inc. (CARA)

Joana Goncalves

FY2023 is the first fiscal year CompBrief holds for Joana Goncalves as a named executive officer of Tvardi Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,273,996

Salary $500,240Stock awards $0

2nd of 3 named executive officers at Tvardi Therapeutics by FY2023 total.

3 named officers on file for Tvardi Therapeutics, FY2023

Joana Goncalves’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tvardi Therapeutics’s whole pay program stands against its peers

  • Tvardi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CARA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 1, 1900 (DEF 14A).

Free

Get Joana Goncalves’s full pay file as a PDF — free

More than this page: up to 10 years of Joana’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joana Goncalves compensation by year

Tvardi Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Tvardi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$500,240
Bonus$0
Stock awards$0
Option awards$573,156
Non-equity incentive$190,091
Pension and deferred compensation$0
All other$10,509
Total$1,273,996

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tvardi Therapeutics, Inc. DEF 14A filed January 1, 1900, accession 0001104659-24-049971, and prior-year filings.

How this page was built: the Tvardi Therapeutics, Inc. filed document, accession 0001104659-24-049971. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU40,000$29,720—
RSU13,334$9,907—
RSU5,334$3,963—
Option1,334—$16.36
Option10,000—$20.59
Option43,334—$10.46
Option65,813—$10.06

Per the Outstanding Equity Awards at Fiscal Year-End table in Tvardi Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Tvardi Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Christopher PosnerPresident and Chief Executive Officer$2,922,469
Joana Goncalves · this pageformer Chief Medical Officer$1,273,996
Ryan MaynardChief Financial Officer$1,243,857

The full Tvardi Therapeutics compensation record

free company brief

This page is one person within Tvardi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tvardi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joana Goncalves's compensation dossier · One-time report. No refunds.